THP

DRUG3 trials

Sponsors

Fudan University, Shanghai Henlius Biotech, Peking University People's Hospital

Conditions

Breast Cancer (Early Breast Cancer)HER2 + Breast CancerHER2-positive Breast Cancer

Phase 2

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

Not yet recruitingNCT06548178

Fudan UniversityHER2-positive Breast Cancer

Start: 2024-09-30End: 2028-09-30Target: 242Updated: 2024-08-12

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer

RecruitingNCT07294508

Shanghai Henlius BiotechHER2 + Breast Cancer

Start: 2026-02-27End: 2030-12-30Target: 706Updated: 2026-03-20

Unknown Phase

A Prospective, Open-label, Randomized Trial Comparing Switch to A1811 Versus Continued THP Neoadjuvant Therapy After THP Induction in HER2-Positive Breast Cancer

Not yet recruitingNCT07844291

Peking University People's HospitalBreast Cancer (Early Breast Cancer)

Start: 2026-11-01End: 2031-12-31Target: 432Updated: 2026-09-28